November 12, 2024CorporateTerumo Blood and Cell Technologies Merges Therapeutics Units to Enhance Patient Care Across Treatment JourneyNew Global Therapy Innovations business unit, led by Veerle d’Haenens, aims to unify therapeutic apheresis and cell and gene therapy expertise to expand therapeutic possibilities
November 07, 2024FinancialNotice Concerning Revisions to Full-Year Consolidated Financial Guidance for Fiscal Year Ending March 31, 2025 (FY2024) (PDF 85.27 KB)
The Latest Materials 1st Half Financial Results for FYE 3/2025 November 07, 2024 Financial Statements IFRS Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2025 (PDF 420.15 KB) Presentation Material Beyond GS26: Innovation Strategy (PDF 2.51 MB) Financial Results for the Second Quarter of Fiscal Year Ending March 31, 2025 (FY2024) (PDF 1.16 MB) Financial Results for the Second Quarter of Fiscal Year Ending March 31, 2025 (FY2024)(with note) (PDF 392.11 KB) Additional Information Corporate Data File for the Second Quarter of FY 2024 (PDF 565.49 KB) Corporate Data File for the Second Quarter of FY 2024 (Excel 302.25 KB) Q&A Q&A Session at the Financial Results Briefing for the Second Quarter of Fiscal Year Ending March 31, 2025 (PDF 153.17 KB) Webcast Listen to the Webcast Financial Statements /investors/library/financial-statements Presentations /investors/library/presentations Terumo Report /investors/library/annual-reports Sustainability /sustainability Corporate Governance /about/governance Consolidated Financial Statements /investors/library/financial Adobe Reader is required for viewing PDF files. Download Adobe Reader
IFRS Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2025 (PDF 420.15 KB)
Financial Results for the Second Quarter of Fiscal Year Ending March 31, 2025 (FY2024)(with note) (PDF 392.11 KB)
Q&A Session at the Financial Results Briefing for the Second Quarter of Fiscal Year Ending March 31, 2025 (PDF 153.17 KB)